Translational Research Office (TRO)


Creating new business links at the largest Advanced Therapies Congress

21 March 2024

The UCL Translational Research Office (TRO) partnered with UCL Business (UCLB), our technology transfer office, to exhibit at this year’s Advanced Therapies Congress at ExCel, London, engaging with experts in cell and gene therapy from around the world.

A photo showing an ongoing panel discussion with a group of audience inside an event venue.

Photo 1: Dr. Pamela Tranter, Head of the Translational Research Group within the UCL Translational Research Office, spoke at a panel discussion addressing the educational and training needs for the future.

The two-day Advanced Therapies Congress concluded on 20 March 2024, with a record-breaking number of over 2,000 attendees from across the ATMP space exchanging ideas on cell and gene therapy. The TRO was pleased joined hands with UCLB to participate in the event by hosting an exhibition booth, introducing delegates to UCL's extensive translational biomedical network and its partner hospitals, with the aim of fostering connections within the wider ATMP community.

UCL has one of the most extensive Advanced Therapy Medicinal Products (ATMP) pipelines in the world, with over 100 projects in development. Its extensive experimental know-how spans across disciplines, highlighting specialisms in Rare Diseases, Ophthalmology, Haematology/Oncology, Neurology, and Immunology. Twelve successful spinouts in advanced therapeutics, five of which have received collective external investment of over £2bn. 

Statistics* also show that 54% of all UK academic-sponsored clinical trials and 43% of all UK commercial-sponsored clinical trials are conducted by UCL partner hospitals, demonstrating UCL’s leading position in delivering these complex therapies.

Graphics showing the statics of Cell and Gene Therapy clinical trials in 2023

*Graphic 1: Data from Cell and Gene Therapy Catapult UK Clinical Trials Database 2023


At TRO, our mission is to support and nurture key partnerships in the ecosystem to advance the biomedical therapy pipeline and deliver biomedical impact. We eagerly anticipate continuing conversations with the ATMP community and extend our gratitude to everyone who connected with us at the event, paving the way for potential collaborations.


Contact us:
If you are a UCL researcher looking for translational research consultation or funding application support, please contact: 
Pamela Tranter, p.tranter@ucl.ac.uk

If you are an industry partner looking for collaboration opportunities with UCL, please contact: 
Basma Jeelani, b.jeelani@ucl.ac.uk


A photo showing an exhibition booth with three staff members

Photo 2:
Healthcare business and innovation managers, along with colleagues from the UCL Translational Research Office (TRO) and UCL Business (UCLB), attended the Advanced Therapies Congress to engage with cell and gene therapy experts from around the world


A photo showing a conference space with groups of people around the exhibition booths
A photo showing a conference space with groups of people around the exhibition booths

Photo 3 – 4:
The event has generated numerous discussions about UCL’s ATMP capabilities and collaboration potential among colleagues from the UCL Translational Research Office, UCL Business, and other ATMP experts attending the event.


  • Interested to stay informed of upcoming news, events and funding calls?

  • Subscribe to our newsletter and you would automatically become a member of UCL TINs (Therapeutic Innovation Networks) and be the first to receive our event invitations

  • Follow us on social media (LinkedInTwitter) and stay tuned to our news and updates.